Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
GPRC5D is an orphan G protein-coupled receptor in class C group 5, characterized as a seven-pass transmembrane receptor with a short extracellular N-terminal domain. It shows overexpression associated with plasma cell burden and genetic aberrations in multiple myeloma, with low expression in normal tissues, making it a selective surface target. Unlike some antigens, it is unlikely to be shed into serum, potentially reducing efficacy sinks for therapies. It is targeted by T-cell redirecting agents like bispecific antibodies and CAR T cells, achieving high response rates (≥64% overall, with many very good partial responses or better) in relapsed/refractory multiple myeloma patients.
T-cell redirection (bispecific antibodies and CAR T cells targeting GPRC5D and CD3)
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on G protein-coupled receptor class C group 5 member D (GPRC5D) (GPRC5D).